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Abstract: OBJECTIVES To derive and externally validate a copeptin-based parsimonious score to predict
unfavorable outcome 3 months after an acute ischemic stroke (AIS). METHODS The derivation cohort
consisted of patients with AIS enrolled prospectively at the University Hospital Basel, Switzerland. The
validation cohort was prospectively enrolled after the derivation cohort at the University Hospital of Bern
and University Hospital Basel, Switzerland, as well as Frankfurt a.M., Germany. The score components
were copeptin levels, age, NIH Stroke Scale, and recanalization therapy (CoRisk score). Copeptin levels
were measured in plasma drawn within 24 hours of AIS and before any recanalization therapy. The
primary outcome of disability and death at 3 months was defined as modified Rankin Scale score of 3
to 6. RESULTS Overall, 1,102 patients were included in the analysis; the derivation cohort contributed
319 patients, and the validation cohort contributed 783. An unfavorable outcome was observed among
436 patients (40%). For the 3-month prediction of disability and death, the CoRisk score was well
calibrated in the validation cohort, for which the area under the receiver operating characteristic curve
was 0.819 (95% confidence interval [CI] 0.787-0.849). The calibrated CoRisk score correctly classified
75% of patients (95% CI 72-78). The net reclassification index between the calibrated CoRisk scores with
and without copeptin was 46% (95% CI 32-60). CONCLUSIONS The biomarker-based CoRisk score for
the prediction of disability and death was externally validated, was well calibrated, and performed better
than the same score without copeptin. CLINICALTRIALSGOV IDENTIFIER NCT00390962 (derivation
cohort) and NCT00878813 (validation cohort).
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To derive and externally validate a copeptin-based parsimonious score to predict unfavorable
outcome 3 months after an acute ischemic stroke (AIS).
Methods
The derivation cohort consisted of patients with AIS enrolled prospectively at the University
Hospital Basel, Switzerland. The validation cohort was prospectively enrolled after the deri-
vation cohort at the University Hospital of Bern and University Hospital Basel, Switzerland, as
well as Frankfurt a.M., Germany. The score components were copeptin levels, age, NIH Stroke
Scale, and recanalization therapy (CoRisk score). Copeptin levels were measured in plasma
drawn within 24 hours of AIS and before any recanalization therapy. The primary outcome of
disability and death at 3 months was defined as modified Rankin Scale score of 3 to 6.
Results
Overall, 1,102 patients were included in the analysis; the derivation cohort contributed 319
patients, and the validation cohort contributed 783. An unfavorable outcome was observed
among 436 patients (40%). For the 3-month prediction of disability and death, the CoRisk
score was well calibrated in the validation cohort, for which the area under the receiver
operating characteristic curve was 0.819 (95% confidence interval [CI] 0.787–0.849). The
calibrated CoRisk score correctly classified 75% of patients (95% CI 72–78). The net reclas-
sification index between the calibrated CoRisk scores with and without copeptin was 46% (95%
CI 32–60).
Conclusions
The biomarker-based CoRisk score for the prediction of disability and death was externally
validated, was well calibrated, and performed better than the same score without copeptin.
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One of the first questions asked by relatives and patients
admitted to the emergency department with an acute ische-
mic stroke relates to their prognosis. Early and accurate
prognostication can individualize counseling, guide triage, and
inform end-of-life decisions.
A contemporary prognostic score should take into account
whether the patient is treated with intravenous or endovas-
cular recanalization therapy because this affects outcome.1,2
This would allow computation of 2 probabilities of unfavor-
able outcome, conditional on thrombolysis. However, the
variables for acute treatment are lacking in the most prom-
inent current prognostic scales.3 Moreover, to be used in the
emergency clinical setting, a prognostic score should be par-
simonious, that is, encompass a low number of items, all fast
and easy to assess. One of the leanest scores contains only 2
variables, age and NIH Stroke Scale (NIHSS) score, and was
validated in the Virtual International Stroke Trials Archive
(VISTA). The score achieved an area under the curve of 0.81
for disability and of 0.71 for mortality 3 months after stroke.4
Such figures can be improved. First, recanalization therapy
status should be accounted for. Second, blood markers may
increase the prognostic accuracy of scores. Recently, copeptin
plasma levels measured on admission to the emergency room
were associated with disability andmortality at 3 months, after
adjustment for age, stroke severity, size of the ischemic lesion,
and other outcome predictors.5,6 Our aim was to derive and
validate a novel biomarker-based parsimonious score for use
in the emergency room using copeptin, one of the most
promising prognostic blood biomarkers in patients with acute
ischemic stroke.
Methods
Standard protocol approvals, registrations,
and patient consents
This study was conducted according to the principles
expressed in the Declaration of Helsinki and was approved by
the ethics committees. All patients or their welfare guardians
provided written informed consent for the collection of data
and blood samples and subsequent analyses.
Patients
The derivation and validation cohorts have been described
previously.5,6 Briefly, the derivation cohort consisted of
consecutive patients with acute ischemic stroke hospitalized at
the University Hospital Basel, Switzerland, between 2006 and
2007 (Copeptin in Osmoregulation and Stress Assessment
[COSMOS] study, ClinicalTrials.gov identifier NCT00390962).
The validation cohort consisted of consecutive patients with
acute ischemic stroke hospitalized at the University Hospital
Bern and University Hospital Basel (Switzerland) and at the
Goethe University Hospital Frankfurt a.M. (Germany) be-
tween 2009 and 2011 (Copeptin for Risk Stratification in
Acute Stroke Patients [CoRisk] Study, ClinicalTrials.gov
identifier NCT00878813). In both cohorts, acute ischemic
stroke was defined as an acute focal neurologic deficit lasting
>24 hours with no sign of acute intracranial bleeding on ce-
rebral imaging.7 Both patients with and those without
thrombolysis were included. Thrombolysis was defined as
either intravenous or endovascular treatment. Patients lost to
follow-up were excluded from the present analysis.
Copeptin measurements
In both the COSMOS and CoRisk studies, blood was drawn
in the emergency room on patient admission. In the COSMOS
study, blood was drawn within 24 hours of stroke onset in 322
patients; we excluded 40 patients from COSMOS in whom
blood was drawn between 24 and 72 hours.5 In the CoRisk
Study, no patient admitted beyond 24 hours of symptom onset
was included, so blood was drawn within 24 hours in all patients
in the emergency room (783 of 783).6 In both cohorts, blood
was always drawn before thrombolysis if performed. Among
patients treated with thrombolysis, an additional venipunc-
ture was performed the day after admission, and copeptin
levels were again assessed. After centrifugation for 20 minutes
at 3,000g at room temperature, plasma was aliquoted from
EDTA tubes. Tubes were frozen locally at each center at
−70°C. Copeptin levels were assessed in plasma in a blinded
batch analysis. Copeptin was measured by a chemiluminescence
sandwich immunoassay, the specifics of which have been
reported elsewhere.8 In 359 healthy individuals, median copeptin
levels were reported to be 4.2 pmol/L with a 99th percentile of
13.5 pmol/L.8
Endpoints
In both cohorts, trained vascular neurologists and study
nurses assessed outcome 3 months after acute stroke either
during an outpatient visit (for patients who underwent
thrombolysis) or with a structured follow-up telephone in-
terview. They were blinded to copeptin levels and baseline
Glossary
ASTRAL = Acute Stroke Registry and Analysis of Lausanne; AUC = area under the receiver operating characteristic curve;CI =
confidence interval; CoRisk = Copeptin for Risk Stratification in Acute Stroke Patients; COSMOS = Copeptin in
Osmoregulation and Stress Assessment; JURaSSIC = Clinician Judgment Versus Risk Score to Predict Stroke Outcomes;
mRS = modified Rankin Scale; NIHSS = NIH Stroke Scale; NRI = net reclassification index; PLAN = preadmission
comorbidities, level of consciousness, age, and neurologic deficit; SOAR = stroke subtype, Oxfordshire Community Stroke
Project, age, and prestroke modified Rankin Scale; THRIVE = Totaled Health Risks in Vascular Events; VISTA = Virtual
International Stroke Trials Archive.
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clinical variables, including patient demographics and
treatment.5,6
In both cohorts, the 2 primary endpoints were unfavorable
functional outcome and death, defined as a modified Rankin
Scale (mRS) score of 3 to 6, and mortality 3 months after
stroke onset.5,6
Statistics
Two logistic regression models were fitted: one for modeling
unfavorable functional outcome or mortality (mRS score
3–6) vs favorable functional outcome (mRS score ≤2) and
a second one for modeling mortality vs survival within 3
months after stroke.
As a first step, we used only age, NIHSS score on admission,
and thrombolysis as variables in the logistic regression model.
Subsequently, we added log10-transformed copeptin levels.
The reason we chose age, NIHSS score, and copeptin as
covariates was that they were the only 3 variables that were
independently associated with 3-month functional outcome
and mortality in both the derivation and validation cohorts.5,6
The reason for including thrombolysis was its evidence on
outcome improvement (Class I, Level A).9 In every model, we
confirmed that there was no indication of a nonlinear effect
for copeptin, age, NIHSS score, or thrombolysis using mul-
tivariable fractional polynomials.
When an existing model is transferred to another population
with a different prevalence of the event, the predicted prob-
abilities might be systematically too low or too high; that is,
there is an error in calibration.9 Calibration was assessed by
calibration curves for which predicted probabilities are plotted
against true probabilities for grouped observations. Grouping
of observations is necessary to derive true probabilities from
patients’ status by taking the relative frequency of the class of
interest in that group. We used an average number of 40
observations per group to generate the figure with the cali-
bration curves. In the case of perfectly calibrated probabilities,
all observations lie on the 45° diagonal. Both models were
recalibrated for logistic regression.10 In this approach, a lo-
gistic regression model was built on the COSMOS data first,
and the regression coefficients were fixed. Then, the intercept
was estimated anew with the CoRisk data (validation cohort)
and 10-fold cross-validation while all other regression coef-
ficients were kept unchanged. We called the calibrated model
with log10 (copeptin), age, NIHSS score, and thrombolysis
the CoRisk score. The Brier score11 was used to measure
prediction performance. The Brier score is the mean of the
squared difference between patient status and predicted
probability. Thus, small values for the Brier score indicate
good prediction accuracy. To assess the discriminative value
of the model with and without copeptin, the area under the
receiver operating characteristic curve (AUC) was calculated
and compared. To identify clinically meaningful copeptin
cutoffs, we proceeded as follows. First, in the derivation co-
hort, we identified cutoffs with a sensitivity of ≥80% and the
highest specificity and cutoffs with a specificity of ≥80% and
the highest sensitivity. Then, in the validation cohort, we
computed the sensitivity and specificity of such cutoff values.
To assess the statistical significance of the AUC change be-
tween the model without copeptin vs the model with
copeptin, we used the likelihood ratio test as recommended
for nested regression models.12 The continuous net reclassi-
fication index (NRI) was calculated from the proportions of
individuals with increased and decreased predicted probabil-
ity when the predictions of 2 models, with and without
copeptin, are compared.13 Two-sided values of p < 0.05 were
considered significant.
We used the statistical software R 3.3.0 for analysis. The R
package mfp was used for calculating multivariable fractional
polynomials; the R package rms was used for plotting the
calibration curves; the R package ROCR (R package version
1.0–7) was used for calculating the AUC; and the R package
Hmisc was used for calculating the NRI.
Results
Overall, a total of 1,102 patients were included in the analysis.
The derivation cohort contributed 319 patients, and the val-
idation cohort contributed 783 patients. Patients lost to
follow-up were excluded (derivation cohort 3 patients, vali-
dation cohort 5 patients). The reasons for loss to follow-up
were unclear. The 2 cohorts were geographically in-
dependent: in the derivation cohort, all patients were admit-
ted to the University Hospital Basel (Switzerland); in the
validation cohort, 740 patients (95%) were admitted to the
University Hospital Bern (Switzerland), 25 (3%) to Goethe
University Hospital Frankfurt a.M. (Germany), and 18 (2%)
to the University Hospital Basel. The baseline characteristics
of the 2 cohorts are summarized in table 1. In the derivation
cohort, 65 patients (20%) were treated with thrombolysis
(intravenous thrombolysis [n = 59, 91%], endovascular
treatment [n = 6, 9%], intravenous and endovascular treat-
ment [n = 0, 0%]). In the validation cohort, 318 patients
(41%) were treated with thrombolysis (intravenous throm-
bolysis [n = 160, 50%], endovascular [n = 123, 39%], in-
travenous and endovascular [n = 35, 11%]).
At 3 months, unfavorable outcomes were observed in 136
patients (43%) of the derivation and 300 patients (38%) of
the validation cohort. The original score and the CoRisk score
(i.e., the recalibrated original score) are reported in table 2,
and the respective calibration curves are displayed in figure 1.
The CoRisk score showed good congruence between pre-
dicted and observed 3-month functional outcome. The for-
mula to predict unfavorable 3-month outcome is reported
in table 3, along with 2 examples. As convenience tools, an
online calculator and Android app are available.14,15 The
sensitivity and specificity of copeptin cutoff values are
reported in table 4. Adding copeptin to the calibrated model
with age, NIHSS score, and thrombolysis increased the area
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under the curve from 0.816 (95% confidence interval [CI]
0.785–0.846) to 0.819 (95% CI 0.787–0.849, plikelihood ratio test
< 0.001, figure 2); that is, the probability that the CoRisk score
assigns a higher probability for an unfavorable 3-month out-
come to patients with an unfavorable outcome than to
patients with a favorable outcome is 81.9%. Overall, 75%
(95% CI 72%–78%) of patients were classified correctly. At
a CoRisk score cutoff of 0.43 (or 43% of estimated probability
of unfavorable outcome at 3 months), the sensitivity was 67%
(95% CI 62%–72%) and specificity was 80% (95% CI
76%–83%).
The overall NRI between the calibrated models without and
with added copeptin levels was 0.46 (95% CI 0.32–0.60).
Among those patients with a good 3-month functional
outcome, a net of 0.35 (95% CI 0.26–0.43) was moved to
a lower risk-category; among those with an unfavorable out-
come, a net of 0.11 (95% CI 0.001–0.23) was moved to
a higher risk category. Among patients treated with throm-
bolysis, the change in copeptin blood levels before and after
thrombolysis was not associated with 3-month outcome in
either the derivation or validation cohort (data not shown).
Death within 3 months occurred in 38 patients (12%) of the
derivation and 118 patients (15%) of the validation cohort.
The calibration plot in figure 3 shows that the logistic re-
gression model with age, NIHSS score, copeptin, and
thrombolysis did not fit well. Recalibration could not improve
the model fit; therefore, the model was not accurate for the
prediction of mortality at 3 months.
Discussion
The CoRisk score could be derived and externally validated in
a geographically and chronologically independent cohort.
The novel features of the CoRisk score are the inclusion of
a validated prognostic blood marker, copeptin, and throm-
bolysis to predict functional outcome 3 months after an is-
chemic stroke. Conditional on thrombolysis status, the
CoRisk score allows computation of 2 distinct probabilities of
3-month disability. Albeit statistically significant, the numeric
increase in the AUC curves between the predictive models
without and with copeptin was modest. At the same time, the
inclusion of copeptin in the model was associated with an NRI
of 46%, indicating that copeptin allowed improvement in risk
reclassification in almost every second patient. This im-
provement is clinically relevant when it comes to accurately
Table 1 Patient characteristics in the derivation (COSMOS) and validation (CoRisk) cohort
Derivation cohort (n = 319) Validation cohort (n = 783)
Age, median (IQR), y 75 (64–83) 71 (60–80)
NIHSS score, median (IQR) 5 (3–10) 6 (3–13)
Thrombolysis, n (%) 65 (20) 318 (41)
Copeptin, median (IQR), pmol/L 12.2 (6.0–24.3) 14.2 (5.9–46.5)
Total anterior circulation syndrome, n (%) 37 (12) 158 (20)
Modified Charlson comorbidity index score, median (IQR) 1 (0–2) 0 (0–1)
C-reactive protein, median (IQR), mg/L 3.2 (3.0–8.8) 3.0 (3.0–6.0)
Blood glucose, median (IQR), mmol/L 6.1 (5.5–7.4) 6.3 (5.5–7.5)
Stroke onset to venipuncture <3 h, n (%) 78 (24) 359 (46)
3-mo follow-up, n (%)
Unfavorable functional outcomea 136 (43) 300 (38)
Mortality 38 (12) 118 (15)
Abbreviations: IQR = interquartile range; CoRisk = Copeptin for Risk Stratification in Acute Stroke Patients; COSMOS = Copeptin in Osmoregulation and Stress
Assessment; NIHSS = NIH Stroke Scale.
a Unfavorable functional outcome at 3 months was defined as a modified Rankin Scale score of 3 to 6, meaning disability or death.
Table 2 Estimated regression coefficients of the original
and recalibratedmodel (CoRisk score) predicting
unfavorable functional outcomea at 3 months
Original Standard error CoRisk score
Intercept −7.131 1.123 −7.202
Age 0.057 0.013 0.057
NIHSS 0.220 0.035 0.220
Thrombolysis −2.054 0.531 −2.054
Log10 (copeptin)
b 1.185 0.357 1.185
Abbreviations: CoRisk = Copeptin for Risk Stratification in Acute Stroke
Patients; NIHSS = NIH Stroke Scale.
a Unfavorable functional outcome at 3 months was defined as a modified
Rankin Scale score of 3 to 6, meaning disability or death.
b Copeptin expressed in pmol/L.
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estimate prognosis, on which triage decisions, acute man-
agement decisions, and end-of-life decisions are based.
However, for the prediction of death vs survival, the model
was not well calibrated, so we were not able to provide an
accurate score for the second outcome measure.
Including thrombolysis in the CoRisk score accounts for the
progress made in the last 2 decades in the treatment for acute
ischemic stroke.1,2 An item for thrombolysis was lacking in all
of the 8 prognostic scores published in leading clinical jour-
nals since 2000 and compared head to head in 2017.3 The
prognostic scores were Acute Stroke Registry and Analysis of
Lausanne (ASTRAL) score; iScore; iScore-revised; pre-
admission comorbidities, level of consciousness, age, and
neurologic deficit (PLAN); stroke subtype, Oxfordshire
Community Stroke Project, age, and prestroke modified
Rankin Scale (SOAR); modified SOAR; Stroke Prognosis
Instrument 2; and Totaled Health Risks in Vascular Events
(THRIVE).3 In the derivation and validation studies of the 8
prognostic scores, patients treated with thrombolysis were not
explicitly excluded, with the exception of PLAN. In PLAN,
patients treated with thrombolysis were excluded from the
primary analysis and assessed in a post hoc analysis, which
revealed a reduced prognostic accuracy among patients trea-
ted with thrombolysis (AUCno thrombolysis = 0.77 vs AUC-
thrombolysis = 0.72). The reduction in prognostic accuracy likely
results from thrombolysis affecting outcomes, thus compli-
cating prognostication if not accounted for.
Figure 1 Calibration curves for the original model and recalibrated model (CoRisk score) for the prediction of unfavorable
functional 3-month outcome
(A) Calibrated and (B) not calibrated. CoRisk = Copeptin for Risk Stratification in Acute Stroke Patients.
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The THRIVE score was derived among patients from 2
single-arm trials testing a thrombectomy device (MERCI and
Multi-MERCI), and was externally validated in the MERCI
registry.16,17 In addition, THRIVE was validated in a cohort
from the National Institute of Neurological Disorders and
Stroke tissue plasminogen activator trial, which compared
intravenous thrombolysis to placebo among patients admitted
within 3 hours of stroke onset.18 In all 3 studies, as the
THRIVE score increased, the chances of a good outcome
decreased. Increased chances of a good outcome were asso-
ciated with vessel recanalization and use of intravenous
thrombolysis. Thus, there are 3 groups of stroke patients in
whom THRIVE has been validated: patients receiving endo-
vascular treatment, patients receiving intravenous thrombol-
ysis, and patients receiving no intravenous therapy despite
qualifying for it (according to the National Institute of Neu-
rological Disorders and Stroke tissue plasminogen activator
randomization protocol). The last group, however, does not
reflect everyday clinical practice because we do not withhold
intravenous therapy in patients qualifying for it. Instead, in
clinical practice, we withhold intravenous thrombolysis be-
cause of delayed hospital admission (i.e., beyond the time
window of 3–4.5 hours) or contraindications (e.g., in-
ternational normalized ratio >1.7). Therefore, in clinical
practice, the THRIVE score cannot be applied to those stroke
patients who receive no recanalization therapy, that is, the
majority of all stroke patients. On the other hand, the CoRisk
score addresses this need because it has been validated for
stroke patients admitted within 24 hours of stroke onset. The
CoRisk score can be applied to that majority of stroke patients
who receive no recanalization therapy and allows computa-
tion of their chances of unfavorable outcome. While prog-
nostic scores have been derived and validated for patients
treated with thrombolysis (DRAGON,19 SEDAN,20 SPAN-
10021), the CoRisk score applies to a broader range of stroke
patients admitted within 24 hours from stroke onset, treated
with or without thrombolysis.
Among the 8 assessed stroke prognostic scores, ASTRAL had
the greatest prognostic accuracy.3 For the derivation and
validation of the ASTRAL score, the same definition of un-
favorable outcome as for the CoRisk score, that is, mRS score
of 3 to 6, was used.22 The ASTRAL score is an integer-based
score encompassing 6 items (age, NIHSS score on admission,
stroke onset to admission time, range of visual fields, acute
glucose, and level of consciousness). The ASTRAL score was
derived in 1,645 patients from the ASTRAL (Switzerland)
and was validated in 2 independent cohorts (Athens [n = 1,659]
and Vienna Stroke [n = 653] registries). In the pooled validation
cohorts, the AUC of the ASTRAL scores was 0.902, and the
ASTRAL score was well calibrated.22 When validated in the
VISTA cohort, ASTRAL score achieved an AUC of 0.79.3
Compared to the ASRTRAL score, the CoRisk score has 3 fewer
items and does not include visual fields, which can be difficult, if
not impossible, to assess in aphasic or somnolent patients.
The blood marker copeptin increases the prognostic accuracy
beyond age, NIHSS score, and thrombolysis status, keeping
the CoRisk score “lean” with only 4 items. The NRI for func-
tional outcome in the current study (46%) is higher than the
NRI reported in the original studies on copeptin (39.3%5 and
11.8%6). The main reason is that, in the current study, we
computed the continuous NRI as opposed to the categorical
NRI in the original copeptin studies. For a prognostic tool such
as the CoRisk score, we believe that any change in classification,
even small ones, can be clinically meaningful to the patient and
proxies, so we preferred not to specify any risk categories.
All items are suited for early prognostication, given the short
incubation time of 30 minutes needed to assess copeptin
plasma levels.8 The pathophysiologic link between copeptin
Table 4 Sensitivity and specificity of copeptin blood levels
for unfavorable functional outcomea at 3months
Copeptin cutoff, pmol/L Sensitivity, % Specificity, %
Derivation cohort (AUC = 0.71)
≥7.32 80 39
≥19.60 49 80
Validation cohort (AUC = 0.71)
≥7.32 84 40
≥19.60 65 70
Abbreviation: AUC = area under the curve.
a Unfavorable functional outcome at 3 months was defined as a modified
Rankin Scale score of 3 to 6, meaning disability or death.
Table 3 CoRisk score for the prediction of unfavorable 3-month outcome
Probability of unfavorable 3-month outcome = 1
1 + e7:202−0:057  ðAge in yearsÞ−0:220  ðNIHSS pointsÞ+2:054  ðThrombolysis  ½yes=1; no=0Þ−1:185  Log10   ðcopeptin  ½pmol=LÞ
Examples
The CoRisk online calculator and an Android app are available.14,15
A 75-y-old patient with an NIHSS score of 7 who received no thrombolysis and had a copeptin blood level of 11.0 pmol/L has a 46% probability of
unfavorable 3-mo outcome.
The same patient with a copeptin blood level of 110.0 pmol/L (10-fold higher) has a 74% probability of unfavorable 3-mo outcome.
Abbreviations: CoRisk = Copeptin for Risk Stratification in Acute Stroke Patients; NIHSS = NIH Stroke Scale.
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and outcome is unclear. Copeptin, secreted from the
hypothalamo-pituitary axis into the peripheral blood, acts as an
“endogenous barometer of integral homeostasis.”23 Thus,
copeptin assesses the severity of damage beyond age, measurable
clinical impairment on admission, and ischemic lesion size.23
For outcome prognostications, validated scores perform
better than clinicians.24,25 A recent study compared the
ASTRAL score to estimates of 244 clinicians with expertise in
stroke for 720 real stroke scenarios for the prediction of
3-month mRS score of 3 to 6 in the general ischemic stroke
population.25 Overall, 86.5% of ASTRAL-based estimates
were accurate, as opposed to 56.8% of estimated by clinicians
with expertise in stroke. The majority of the physicians’ in-
accurate estimates (n = 231, 76.0%) were overly pessimistic,
that is, overestimated the probability of unfavorable outcome
Figure 3 Calibration curves for the original model and recalibrated model (CoRisk score) for the prediction of 3-month
mortality
(A) Calibrated and (B) not calibrated. CoRisk = Copeptin for
Risk Stratification in Acute Stroke Patients.
Figure 2 Receiver operating characteristic curve of the CoRisk score for the prediction of unfavorable 3-month outcome
CoRisk = Copeptin for Risk Stratification in Acute Stroke
Patients.
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at 3 months. Wrong prognostication misleads patients and their
relatives, compromises end-of-life decisions, and undermines
a cost-effective allocation of health care resources.
The Clinician Judgment Versus Risk Score to Predict Stroke
Outcomes (JURaSSIC) study compared the iScore to the
estimates of 111 clinicians with expertise in stroke for the
prediction of death or disability at discharge (mRS score 3–6)
in 1,415 representative stroke cases.24 While 90% of the
iScore-based estimates were within the 95% CI of observed
outcomes, only about 1 in 6 clinicians (16.9%) was accurate
for the prediction of death or disability at discharge. Here,
clinicians tended to be overly optimistic, and vascular neurologists
were not significantly more accurate than internists, emergency
physicians, or general neurologists. Nearly half of the clinicians
(48%) did not accurately predict the probability of the primary
outcome in any of the 5 rated ischemic stroke scenarios.24
The CoRisk score has strengths and limitations. Strengths of
the CoRisk score are the derivation and validation in 2
chronologically and geographically independent, large
cohorts and the elevated prognostic accuracy despite having
only 4 variables, all easily accessible in the emergency de-
partment.While brain imaging, including advancedmodalities
such as perfusion CT and MRI, provide information linked to
outcome (e.g., infarct core size, tissue at risk), using a blood
marker for prognostication has distinct advantages. First, the
copeptin assay is available around the clock, whereas this is
not the case for advanced imaging modalities in many emer-
gency departments. A point-of-care tool for copeptin blood
levels could shorten the turnaround to seconds. Second,
copeptin blood levels can be easily interpreted through an
online calculator to compute the validated CoRisk score,
while the interpretation of brain imaging for prognostic pur-
poses is more cumbersome because it considers not only
infarct core size but also its neurotopographic location. Third,
the costs of the copeptin assay are lower than those of urgent
brain imaging, including its interpretation for prognostic aims,
a task requiring highly skilled professionals. A limitation of the
CoRisk score is the lack of validation for mortality prediction,
which may be due to the low numbers of deaths along with
different practices on withdrawal of care between the deri-
vation and validation cohort. This may explain why the NRI
for mortality was accurate in the original cohorts, as opposed
to the current study in which findings from the derivation
cohort are translated to the validation cohort. Because we did
not collect data on do-not-resuscitate orders, we were not able
to explore this hypothesis. Another limitation is the baseline
differences between the derivation and validation cohort,
which may have contributed to a higher proportion of un-
favorable outcomes in the derivation cohort (+5 percent
points). In particular, in the derivation cohort, the following
baseline characteristics can explain the higher proportion of
unfavorable 3-month outcomes: higher age, lower throm-
bolysis rate, and higher Charlson comorbidity index score.
Such differences are likely to be inherent to the 2 cohorts,
which were chronologically and geographically independent.
The external validation of the CoRisk score despite such
differences argues for its applicability to predict 3-month
functional outcome among patients with an acute ischemic
stroke. Finally, the CoRisk score is not a tool to select patients
for thrombolysis or endovascular treatment because the
CoRisk score was not developed to predict vessel re-
canalization, a crucial outcome predictor after thrombolysis.26
Further prospective studies should assess the prognostic ac-
curacy of copeptin in the context of other biomarkers. In
addition, future studies should unravel whether the associa-
tion between copeptin blood levels and stroke outcome is
only an epiphenomenon or whether it reflects a causal re-
lationship. The CoRisk score is a novel biomarker-based,
ready-for-use, parsimonious, validated score for the prediction
of disability at 3 months after an acute ischemic stroke.
Author contributions
Gian Marco De Marchis: drafting/revising the manuscript,
data acquisition, study concept or design, analysis or in-
terpretation of data, accepts responsibility for conduct of re-
search and will give final approval, contribution of vital
reagents/tools/patients, statistical analysis, study supervision,
obtaining funding. Theresa Dankowski: analysis or in-
terpretation of data, accepts responsibility for conduct of re-
search and will give final approval, statistical analysis. Inke
Konig: drafting/revising the manuscript, analysis or in-
terpretation of data, accepts responsibility for conduct of re-
search and will give final approval, statistical analysis. Joachim
Fladt: drafting/revising the manuscript, accepts responsibility
for conduct of research and will give final approval. Felix Fluri:
drafting/revising the manuscript, data acquisition, analysis or
interpretation of data, accepts responsibility for conduct of
research and will give final approval. Henrik Gensicke:
drafting/revising the manuscript, accepts responsibility for
conduct of research and will give final approval, acquisition of
data. Christian Foerch: data acquisition, accepts responsibility
for conduct of research and will give final approval, contri-
bution of vital reagents/tools/patients. Oliver Findling:
drafting/revising the manuscript, data acquisition, accepts
responsibility for conduct of research and will give final ap-
proval, study supervision. Rebekka Kurmann: drafting/revising
the manuscript, accepts responsibility for conduct of research
and will give final approval, acquisition of data. Urs Fischer:
analysis or interpretation of data, accepts responsibility for
conduct of research and will give final approval, acquisition of
data. Andreas Luft: drafting/revising the manuscript, accepts
responsibility for conduct of research and will give final approval,
acquisition of data. Daniela Buhl: drafting/revising the manu-
script, analysis or interpretation of data, accepts responsibility for
conduct of research and will give final approval, acquisition of
data. Stefan Engelter: drafting/revising the manuscript, accepts
responsibility for conduct of research and will give final approval.
Philippe Lyrer: drafting/revising the manuscript, accepts re-
sponsibility for conduct of research and will give final approval,
acquisition of data, study supervision. Mirjam Christ-Crain:
drafting/revising the manuscript, study concept or design,
e1524 Neurology | Volume 92, Number 13 | March 26, 2019 Neurology.org/N
Copyright © 2019 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
accepts responsibility for conduct of research and will give final
approval. Marcel Arnold: drafting/revising the manuscript, data
acquisition, study concept or design, accepts responsibility for
conduct of research and will give final approval, study su-
pervision. Mira Katan: drafting/revising the manuscript,
data acquisition, study concept or design, analysis or in-
terpretation of data, accepts responsibility for conduct of
research and will give final approval, statistical analysis,
study supervision, obtaining funding.
Study funding
This study was supported by an unrestricted research grant
from Thermo Fisher Scientific, Thermo Scientific Bio-
markers, Clinical Diagnostics, Neuendorfstr. 25; by 16,761
Hennigsdorf-Berlin (Germany); by the University of Basel,
Switzerland (Wissenschaftsfond); by the Clinical Trial Units
of the University of Bern (Switzerland) through the De
Quervain research grant for young clinical investigators; by
the Foundation of the Inselspital Bern (Switzerland); by the
Foundation Pro Scientia et Arte, Bern (Switzerland); and by
the Swiss National Science Foundation.
Disclosure
G. De Marchis received an unconditional research grant for
the measurement of Copeptin from BRAHMS GmbH,
Hennigsdorf, Germany. In addition, Gian Marco De Marchis
was or is supported by the following grants: Swiss National
Science Foundation (PBBEP3_139388); Science Funds
(Wissenschaftsfonds) of the University Hospital Basel and
University of Basel; Bangerter-Rhyner-Stiftung; Swisslife
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